Further treatments may be indicated throughout the flea and/or tick season. NEXGARD SPECTRA can be used as part of the seasonal treatment of fleas and ticks (replacing a product authorised for the treatment of fleas/ticks only) in dogs with diagnosed concurrent gastrointestinal worm infestations.Ī single treatment is effective for gastrointestinal worms.Įfficacy of the treatment against flea and tick infestations lasts for one month. Treatment of flea and tick infestations and gastrointestinal worms: The treatment schedule should be based on veterinary diagnosis and on the local epidemiological situation. If the dog does not accept the tablets directly they may be administered with food. The tablets are chewable and palatable to most dogs. Number and strength of tablet to be administeredįor dogs above 60 kg appropriate combinations of chewable tablets should be used. The veterinary medicinal product should be administered in accordance with the following table: If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please inform your veterinary surgeon.Ĩ. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION – very rare (less than 1 animal in 10,000 animals treated, including isolated reports). – rare (more than 1 but less than 10 animals in 10,000 animals treated) – uncommon (more than 1 but less than 10 animals in 1,000 animals treated) – common (more than 1 but less than 10 animals in 100 animals treated) – very common (more than 1 in 10 animals treated displaying adverse reaction(s) The frequency of adverse reactions is defined using the following convention: These occurrences were generally self-limiting and of short duration.Įrythema and neurological signs (convulsions, ataxia and muscle tremors) have been reported very rarely. Vomiting, diarrhoea, lack of energy, decreased appetite and itching were uncommonly observed. Prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm infection) with monthly administration.ĭo not use in cases of hypersensitivity to the active substances or to any of the excipients. Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum ) with monthly administration. Prevention of heartworm disease ( Dirofilaria immitis larvae) with monthly administration. Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. Treatment of demodicosis (caused by Demodex canis ). Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms ( Toxocara canis and Toxascaris leonina ), hookworms ( Ancylostoma caninum, Ancylostoma braziliense and Ancylostoma ceylanicum ) and whipworm ( Trichuris vulpis ). Treatment of tick infestations ( Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus ) in dogs.įleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. Treatment of flea infestations ( Ctenocephalides felis and C. Mottled red to reddish brown, circular shaped (tablets for dogs 2–3.5 kg) or rectangular shaped (tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg, tablets for dogs >15–30 kg and tablets for dogs >30–60 kg).įor the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease ( Dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (L5) and adults of Angiostrongylus vasorum ), thelaziosis (adult Thelazia callipaeda ) and/or treatment of gastrointestinal worm infestations is indicated. NEXGARD SPECTRA 9 mg / 2 mg chewable tablets for dogs 2–3.5 kg NEXGARD SPECTRA 19 mg / 4 mg chewable tablets for dogs >3.5–7.5 kg NEXGARD SPECTRA 38 mg / 8 mg chewable tablets for dogs >7.5–15 kg NEXGARD SPECTRA 75 mg / 15 mg chewable tablets for dogs >15–30 kg NEXGARD SPECTRA 150 mg / 30 mg chewable tablets for dogs >30–60 kg Afoxolaner, milbemycin oximeģ. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)Įach chewable tablet contains the active substances: Manufacturer responsible for batch release :īoehringer Ingelheim Animal Health France SCS,Ģ. NAME OF THE VETERINARY MEDICINAL PRODUCT NEXGARD SPECTRA 9 mg / 2 mg chewable tablets for dogs 2–3.5 kg NEXGARD SPECTRA 19 mg / 4 mg chewable tablets for dogs > 3.5–7.5 kg NEXGARD SPECTRA 38 mg / 8 mg chewable tablets for dogs >7.5–15 kg NEXGARD SPECTRA 75 mg / 15 mg chewable tablets for dogs >15–30 kg NEXGARD SPECTRA 150 mg / 30 mg chewable tablets for dogs >30–60 kgġ. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |